Safety and Efficacy of dulaglutide therapy for perioperative glycaemic control

Safety and Efficacy of dulaglutide therapy for perioperative glycaemic control - Safety and Efficacy of dulaglutide therapy for perioperative glycaemic control

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024342

Enrollment

Registered

2017-04-05

Start date

2016-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type2 diabetes

Interventions

Dulaglutide plus basal insulin group: this group receives dulaglutide once weekly with basal insulin once daily and supplemental dose of regular insulin. Study term is total 8days, 4days before operat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes who need perioperative glycaemic control

Exclusion criteria

Exclusion criteria: Patients admitted to or expected to require ICU admission or cardiac surgery or abdminal surgery; patients with a history of pancreatitis or corticosteroid therapy, clinically relevant hepatic disease,or impaired renal function (serum creatinine >3.0 mg/dL); and patients with a history of diabetic ketoacidosis, pregnancy, or any mental condition rendering the subject unable to give informed consent.

Design outcomes

Primary

Measure	Time frame
Data of CGM pre-operation,post-operation,day1,day2	—

Countries

Japan

Contacts

Public ContactNobutoshi Fushimi

Ichinomiyanishi hospital Department of Endocrinology and Diabetes

nobutoshi243@yahoo.co.jp0586-48-0077

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026